Is memorial sloan-kettering cancer center risk classification appropriate for japanese patients with metastatic renal cell carcinoma in the cytokine era?

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1276-1282

  Shinohara, Nobuo ^a   Abe, Takashige ^a   Mochizuki, Tango ^b   Kashiwagi, Akira ^c   Kanagawa, Kouichi ^d   Maruyama, Satoru ^a   Sazawa, Ataru ^a   Oba, Koji ^e   Nonomura, Katsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO CITY GENERAL HOSPITAL   (Japan)

^c TEINE KEIJINKAI HOSPITAL   (Japan)

^d Asahikawa City Hospital   (Japan)

^e HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

C Index; Metastatic renal cell carcinoma; Prognosis; Risk classification

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ACCURACY; ADULT; AGED; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; JAPANESE; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; VALIDITY;

C-INDEX; METASTATIC RENAL CELL CARCINOMA; PROGNOSIS; RISK CLASSIFICATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; C-REACTIVE PROTEIN; CALCIUM; CARCINOMA, RENAL CELL; FEMALE; HEMOGLOBINS; HUMANS; INTERFERON-ALPHA; JAPAN; KIDNEY NEOPLASMS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84884670729     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.08.009     Document Type: Article

References (18)

1. Interferon-α and survival in metastatic renal carcinoma: Early results of a randomized controlled trial. Lancet 1999, 353:14-17. Medical Research Council Renal Cancer Collaborators.
2. Hudes G., Carducci M., Choueiri T., et al. NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011, 9:S1-S29.
3. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
4. Mekhail T.M., Abou-Jawde R.M., BouMerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841.
5. Tomita Y., Shinohara N., Yuasa T., et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010, 40:1166-1172.
6. Shinohara N., Kumagai A., Kanagawa K., et al. Multi-center phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-α for metastatic renal cell carcinoma. Jpn J Clin Oncol 2009, 39:720-726.
7. Orrell D.H. Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta 1971, 35:483-489.
8. Harrell F.E., Lee K.L., et al. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Medicine 1996, 15:361-387.
9. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon-α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
11. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizmab plus interferon-α-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007, 370:2103-2111.
12. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon-α compared with interferon-α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
13. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
14. Naito S., Yamamoto N., Takayama T., et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1,463 patients. Eur Urol 2010, 57:317-325.
15. Patil S., Ishill N., Deluca J., et al. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer 2010, 116:347-354.
16. Hofmann H.S., Neef H., Krohe K., et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005, 48:77-81.
17. Kanzaki R., Higashiyama M., Fujiwara A., et al. Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: A 25-year single-institution experience. Eur J Cardiothorac Surg 2011, 39:167-172.
18. Patil S., Figlin R.A., Hutson T.E., et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011, 22:295-300.